With all the medical miracles scientists have discovered, pain management is still one area with a lot of holes. Most heavy duty pain killers make you unconscious or just dopey. Then there is that other problem of stomach distress and kidney problems which sometimes accompany use of pain killers and anesthesia.
Dr. Alexander Binshtok of Tel Aviv University’s Sackler School of Medicine might have found the key to killing pain without any of those side effects and its a really hot idea. Binshtok found a way to use chili peppers as a base for a revolutionary new pain killer:
Israeli scientists spice up chronic pain management
By ISRAEL21c staff May 12, 2009
Ask people what they fear most about any medical procedure and they’ll tell you it’s not the operation itself but the pain that goes with it. Anaesthesia also has its drawbacks with side effects like loss of consciousness, wooziness and numbness.
“The holy grail of any local anaesthetic treatment is to stop pain without causing any other effects,” says Dr. Alexander Binshtok of Tel Aviv University’s Sackler School of Medicine. That noble goal may now be within reach with a new approach based on the common chili pepper.
Chili is credited with a variety of healing properties, such as easing the digestive system and clearing congestion. But by joining capsaicin, the substance that makes chili hot, with QX-314, a chemical derivative of the common local anaesthetic lidocaine, Binshtok and his colleagues are able to target selective pain fibers and effectively block the pain.
“We have demonstrated that this method blocks painful stimuli without any side effects,” says Binshtok.
An end to epidurals
The new approach has the potential to change multiple applications of local anaesthesia, from the dental office to the delivery room. Epidurals are one example of a pain management technique that will be revolutionized by this red-hot medication.
Epidural anaesthesia compromises body function to the point where a woman cannot walk and her ability to “push” during labor is limited. With the new pain drug, she will be able to do both painlessly, says Binshtok, thus eliminating the need for an epidural.
Then there is the problem of the pain suffered by millions of Americans with chronic inflammatory diseases, neurogenic diseases, or cancer. “Many people suffer from chronic pain but we don’t understand why,” says Binshtok. “Nobody knows what turns normal or protective pain to chronic or non-protective pain, and we don’t yet understand the agents or molecules that turn normal into chronic pain.”
Binshtok explains that some lucky people carry a specific genetic variance that makes them more resistant not only to pain but to the development of chronic pain after surgery. Understanding this mechanism could be the key to solving pain problems.
As a post-graduate student, Binshtok was part of the research team from Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) that succeeded in selectively blocking pain-sensing neurons in rats without interfering with other types of neurons, giving hope that someday there will be an anaesthetic that blocks pain but doesn’t paralyze or numb the patient.
This fall, Binshtok will be directing his own pain management lab at Tel Aviv University. His work will study what happens on the periphery when painful stimuli attack the skin, and will attempt to understand “how the process is analysed by pain fibers, and then how it is processed by the neurons in the spinal cord” which modify pain signals.
And while he warns there is still more testing and research to be done before a “magic bullet” miracle drug is produced, he is confident that it will come.